New hope for advanced cancers: first human trial launches

NCT ID NCT06265688

Recruiting now Disease control Sponsor: CytomX Therapeutics Source: ClinicalTrials.gov ↗

First seen Feb 28, 2026 · Last updated Apr 28, 2026 · Updated 5 times

Summary

This study tests a new drug, CX-2051, in adults with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety and how well it works, both alone and with another drug called bevacizumab. About 160 participants will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Carolina BioOncology Institute, PLLC
RECRUITING

Huntersville, North Carolina, 28078, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
START San Antonio LLC
RECRUITING

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute at HealthONE
RECRUITING

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute, LLC
RECRUITING

Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR, ADULT